Numerous peptides and proteins with established clinical safety and efficacy have very short pharmacokinetics (therapeutic durability limited by exceptionally short circulating half-lives) that limit their therapeutic and commercial potential.
We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for multiple chronic diseases.
Using PASylation® we can modify our target molecules to safely extend and tune their pharmacokinetics from minutes to months with virtually no impairment of their therapeutic effect and benefit. Our compounds are highly tunable and shelf stable and are designed to be delivered subcutaneously by patients at via a autoinjector.
Antlia is comprised of a dedicated group of scientists focused on developing next-generation long-acting peptide and protein therapeutics to treat chronic cardiovascular and metabolic diseases.
We are driven to make a profound difference in the treatment of cardiovascular and metabolic diseases. Our work is supported by world-class advisors and collaborators and a collective desire to bring life-changing therapeutics to the market.
Copyright © 2023 Antlia Bioscience, Inc. - All Rights Reserved.